id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-336899-zngp67tb	Kadkhoda, Kamran	COVID‐19: are neutralizing antibodies neutralizing enough?	2020-06-03		.txt	text/plain	1211	73	51	The use of convalescent-phase plasma (CP) in severely ill patients with COVID-19 has been attempted on an individual basis 1 and it is being used in the context of ongoing clinical trials; thus, it is pivotal to understand the potential risks and caveats of using CP particularly taking immunopathologic phenomena into account. In this context, previous exposure to common coronaviruses would lead to an early and high-titer immune response to SARS-CoV-2. The donors had neutralizing antibody titers of more than 640 at the time of donation while severely ill patients had relatively similar titers before transfusion as high as 640 (range, 160-640; GMT, 367). 7 The US Food and Drug Administration currently recommends using donated plasma with neutralizing antibody titers of 160 or at a minimum a titer of 80 in severely ill patients.	./cache/cord-336899-zngp67tb.txt	./txt/cord-336899-zngp67tb.txt